#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Haemophagocytic lymphohistiocytosis Ependymoma Scleroderma associated digital ulcer Non-Hodgkin's lymphoma refractory Plasma cell myeloma Waldenstrom's macroglobulinaemia Small intestine neuroendocrine tumour Oesophageal squamous cell carcinoma stage II Central nervous system lymphoma Oesophageal adenocarcinoma stage III Hypochromic anaemia Haemophilia A with anti factor VIII Gastric cancer Craniopharyngioma Pleural mesothelioma malignant More trials…

    Learn about Rare Diseases

    Congenital generalised lipodystrophy Wolfram syndrome – Treatment Mucopolysaccharidosis II – Life with Disease Leiomyosarcoma metastatic – Treatment Sarcoma Haemophilia B with anti factor IX – Treatment Leiomyosarcoma – Basic Information Fragile X syndrome – Basic Information Castleman’s disease – Trials in Disease Small intestine leiomyosarcoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    GUAIACOL Lufepirsen Ezabenlimab Dydrogesterone Pertuzumab Magrolimab Bcmacp03 Indapamide Tulmimetostat Nemvaleukin Alfa Doxazosin Ustekinumab 89ZR-CED88004S Caba-201 Hydroxychloroquine Sulfate Metformin ACICLOVIR SODIUM Vorinostat Fluconazole Specific Nucleic Acid Sna-Ebv More therapies…

    Learn about Your Condition

    Leiomyosarcoma metastatic Bronchostenosis Mesothelioma Endometriosis Allergic respiratory disease Pulmonary fibrosis Macular degeneration Follicular lymphoma stage IV Arterial disorder Eye disorder Multifocal motor neuropathy Mite allergy B-cell lymphoma refractory Hyperinsulinism Liposarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neoplasm malignant

  • Study of BI-1206 and Pembrolizumab for Patients with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Anti-(Fc Fragment Of Igg Receptor Iib) Monoclonal Antibody Bi-1206
    • Pembrolizumab
    Germany Poland Romania Spain Sweden

  • Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Relatlimab
    • Ipilimumab
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    Austria Belgium France Germany Italy Poland +1

  • Study on the Safety and Effectiveness of [90Y]Y-PentixaTher in Patients with Recurrent or Resistant CNS Lymphoma

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Pentixafor
    • Pentixather
    • Gallium (68Ga)
    Germany

  • Study on BI-1808 and Pembrolizumab for Patients with Advanced Solid Tumors

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Bi-1808
    • Pembrolizumab
    Denmark Hungary Spain Sweden

  • Study of drug combination in patients with advanced cancer based on genomic profiling – ProTarget Danish nationwide trial

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Pemigatinib
    • Cobimetinib
    • Niraparib
    Denmark

  • Study on the Safety and Effects of OBT076 and Balstilimab in Patients with Recurrent or Metastatic CD205-Positive Solid Tumors

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Balstilimab
    • Gemcitabine
    Belgium France Greece Spain
Previous Page
1 … 4 5 6 7 8 … 21
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!